
Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma
Keywords: بورتِـزومیب; Proteasome; Bortezomib; Nuclear factor-κB; Radiotherapy; Head-and-neck squamous cell carcinoma;